FealtySign in

HEALTHPEAK PROPERTIES, INC.

(DOC)

CIK 765880 · SEC filings only

Not gradedDividend record
shown as history
company entity
59 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

59 declarations · 9 raised · 47 held · 2 cut · held 16 quarters

  1. HELD$0.3050/shperiod ended 2026-06-30Filing ↗
  2. HELD$0.3050/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.3050/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.3050/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.3050/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.3000/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.3000/shperiod ended 2024-06-30Filing ↗
  8. HELD$0.3000/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.3000/shperiod ended 2023-09-30Filing ↗
  10. HELD$0.3000/shperiod ended 2023-06-30Filing ↗
  11. HELD$0.3000/shperiod ended 2023-03-31Filing ↗
  12. HELD$0.3000/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
2 resolved promises

Not enough resolved promises to grade

2 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (2)

Open · buyback authorization

new $500 million share repurchase authorization

next filing due$500.0Mreceipt →
Open · buyback authorization

Healthpeak's Board of Directors authorized a new $500 million share repurchase program

resolves in ~690 days$500.0Mreceipt →

Credibility timeline

PARTIAL · Oct 25, 2024PARTIAL · Feb 4, 2025
20242025
Timeline as a list
  • Oct 25, 2024PARTIALHealthpeak’s Board of Directors approved a $500 million share repurchase program
  • Feb 4, 2025PARTIALHealthpeak’s Board of Directors approved a share repurchase program authorizing Healthpeak to purchase up to $500 million of common stock
2 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
3 resolved promises

Not enough GAAP-comparable guidance to grade

3 of the 4 resolved guidance promises needed to publish a reliability grade. Much of this company’s guidance is non-GAAP, which has no comparable GAAP actual in SEC XBRL to check it against — shown below, never scored. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (26)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · May 5, 2026
    Diluted earnings per common share from $0.34 – $0.38 to $0.46 – $0.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 2, 2026
    Diluted earnings per common share from $0.34 – $0.38
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 23, 2025
    Diluted earnings per common share from $0.25 – $0.31 to $0.00 – $0.06
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Jul 24, 2025
    Diluted earnings per common share from $0.30 – $0.36 to $0.25 – $0.31
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Apr 24, 2025
    Diluted earnings per common share of $0.30 – $0.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Feb 3, 2025
    Diluted earnings per common share of $0.30 – $0.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Oct 24, 2024
    Diluted Nareit FFO per share from $1.59 – $1.63 to $1.61 – $1.63
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 24, 2024
    Diluted FFO as Adjusted per share from $1.77 – $1.81 to $1.79 – $1.81
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Oct 24, 2024
    Diluted AFFO per share from $1.54 – $1.58 to $1.56 – $1.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Oct 24, 2024
    Diluted earnings per common share from $0.27 – $0.31 to $0.40 – $0.42
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Jul 25, 2024
    Diluted earnings per common share from $0.16 – $0.20 to $0.27 – $0.31
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Apr 25, 2024
    Diluted earnings per common share from $0.07 – $0.13 to $0.16 – $0.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Feb 8, 2024
    Diluted earnings per common share of $0.07 – $0.13
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Oct 30, 2023
    Diluted earnings per common share from $0.49 – $0.53 to $0.53 – $0.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Jul 27, 2023
    Diluted earnings per common share from $0.52 – $0.58 to $0.49 – $0.53
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Apr 27, 2023
    Diluted earnings per common share of $0.52 – $0.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Feb 7, 2023
    Diluted earnings per common share of $0.52 – $0.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Nov 1, 2022
    Diluted earnings per common share from $0.97 – $1.03 to $0.94 – $0.96
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Aug 2, 2022
    Diluted earnings per common share from $0.58 – $0.64 to $0.97 – $1.03
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · May 3, 2022
    Diluted earnings per common share of $0.58 – $0.64
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Feb 8, 2022
    Diluted earnings per common share of $0.58 – $0.64
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Nov 2, 2021
    Diluted earnings per common share from $0.95 – $1.01 to $0.94 – $0.98
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Aug 3, 2021
    Diluted earnings per common share from $0.98 – $1.06 to $0.95 – $1.01
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · May 4, 2021
    Diluted earnings per common share from $1.02 – $1.12 to $0.98 – $1.06
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Feb 9, 2021
    Diluted earnings per common share of $1.02 to $1.12
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Feb 13, 2019
    Diluted net income per share to range between $0.45 to $0.51
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (0) · 2 superseded

Superseded · revenue guidance fy

Blended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 1.50% – 3.00% to 1.75% – 3.25%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Blended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 1.75% – 3.25% to 2.25% – 3.75%

revised by a later guidancereceipt →

Credibility timeline

BEAT · Feb 9, 2022BEAT · Feb 8, 2023BEAT · Feb 3, 2026
20222026
Timeline as a list
  • Feb 9, 2022BEATBlended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 2.25% – 3.75% to 3.50% – 4.00%
  • Feb 8, 2023BEATTotal Portfolio Same-Store Cash (Adjusted) NOI growth of 3.25% – 4.75%
  • Feb 3, 2026BEATTotal Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0% – 4.0%
3 resolved guidance promises · 26dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →